title: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.
abstract: This first update of the ASAS/EULAR recommendations on the management of ankylosing spondylitis (AS) is based on the original paper, a systematic review of existing recommendations and the literature since 2005 and the discussion and agreement among 21 international experts, 2 patients and 2 physiotherapists in a meeting in February 2010. Each original bullet point was discussed in detail and reworded if necessary. Decisions on new recommendations were made - if necessary after voting. The strength of the recommendations (SOR) was scored on an 11-point numerical rating scale after the meeting by email. These recommendations apply to patients of all ages that fulfill the modified NY criteria for AS, independent of extra-articular manifestations, and they take into account all drug and non-drug interventions related to AS. Four overarching principles were introduced, implying that one bullet has been moved to this section. There are now 11 bullet points including 2 new ones, one related to extra-articular manifestations and one to changes in the disease course. With a mean score of 9.1 (range 8-10) the SOR was generally very good.
authors.affiliation: Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany. j.braun@rheumazentrum-ruhrgebiet.de
authors.forename: J
authors.initials: J
authors.lastname: Braun
authors.forename: R
authors.initials: R
authors.lastname: van den Berg
authors.forename: X
authors.initials: X
authors.lastname: Baraliakos
authors.forename: H
authors.initials: H
authors.lastname: Boehm
authors.forename: R
authors.initials: R
authors.lastname: Burgos-Vargas
authors.forename: E
authors.initials: E
authors.lastname: Collantes-Estevez
authors.forename: H
authors.initials: H
authors.lastname: Dagfinrud
authors.forename: B
authors.initials: B
authors.lastname: Dijkmans
authors.forename: M
authors.initials: M
authors.lastname: Dougados
authors.forename: P
authors.initials: P
authors.lastname: Emery
authors.forename: P
authors.initials: P
authors.lastname: Geher
authors.forename: M
authors.initials: M
authors.lastname: Hammoudeh
authors.forename: R D
authors.initials: RD
authors.lastname: Inman
authors.forename: M
authors.initials: M
authors.lastname: Jongkees
authors.forename: M A
authors.initials: MA
authors.lastname: Khan
authors.forename: U
authors.initials: U
authors.lastname: Kiltz
authors.forename: Tk
authors.initials: T
authors.lastname: Kvien
authors.forename: M
authors.initials: M
authors.lastname: Leirisalo-Repo
authors.forename: W P
authors.initials: WP
authors.lastname: Maksymowych
authors.forename: I
authors.initials: I
authors.lastname: Olivieri
authors.forename: K
authors.initials: K
authors.lastname: Pavelka
authors.forename: J
authors.initials: J
authors.lastname: Sieper
authors.forename: E
authors.initials: E
authors.lastname: Stanislawska-Biernat
authors.forename: D
authors.initials: D
authors.lastname: Wendling
authors.forename: S
authors.initials: S
authors.lastname: Ozgocmen
authors.forename: C
authors.initials: C
authors.lastname: van Drogen
authors.forename: Bj
authors.initials: B
authors.lastname: van Royen
authors.forename: D
authors.initials: D
authors.lastname: van der Heijde
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D006801:Humans; D007391:International Cooperation; D017410:Practice Guidelines as Topic; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha